干扰素-α1b治疗慢性乙型肝炎患者对血清肝纤维化标记物的影响

Serum HA,PCⅢ,LN and Ⅳ-C level changes in patients with chronic hepatitis B before and after interferon-α1b treatment

目的 评价干扰素-α1b(赛若金)的抗肝纤维化作用及其与抗病毒疗效的关系。方法 干扰素-α1b治疗57例慢性乙型肝炎患者,对照组用常规方法治疗,检测治疗前后血清透明质酸(HA)、Ⅲ型前胶原(PCⅢ)、层粘连蛋白(LN),Ⅳ型胶原(ⅣC)的含量变化。结果 治疗组疗程结束后,HA、PCⅢ、LN和ⅣC均有不同程度下降,血清HBV DNA阴转者降幅显著大于未阴转者,与对照组比较有显著差异(P<0.05)。结论 赛若金可减轻慢性乙型肝炎患者肝纤维化程度,其抗肝纤维化作用与抗病毒作用呈一致关系。

Objective To study whether the treatment with interferon-α 1b in patients with chronic hepatitis B influence the serum HA,PCⅢ ,LN and Ⅳ-C levels.Methods Serum HA,PCⅢ ,LN and Ⅳ-C levels were detected by RIA in patients with hepatitis B before and after interferon-α1b treatment.Results Serum HA,PCⅢ,LN and Ⅳ-C levels decreased in patients at the end of interferon-α1b treatment and especially in patients with hepatitis B viral DNA negativity. Conclusion The therapy with interferon-α1b for patients with chronic hepatitis B might inhibits the fibrosis process and the anti-fibrosis effect is coincided with the positive response to antiviral treatment.